Allarity Therapeutics (ALLR) Set to Release Quarterly Earnings on Friday

Allarity Therapeutics (NASDAQ:ALLR) is anticipated to issue its results before the market opens on Friday, November 13th. Analysts expect the company to announce earnings of ($0.21) per share for the quarter.

Allarity Therapeutics (NASDAQ:ALLR) last posted its quarterly earnings results on Friday, August 14th. The company reported ($0.21) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.04. On average, analysts expect Allarity Therapeutics to post ($0.80) EPS for the current fiscal year and ($0.86) EPS for the next fiscal year.

Allarity Therapeutics Price Performance

NASDAQ:ALLR opened at $0.91 on Wednesday. The business’s 50-day moving average price is $1.04 and its two-hundred day moving average price is $1.21. Allarity Therapeutics has a 1-year low of $0.77 and a 1-year high of $1.84.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Allarity Therapeutics in a research note on Thursday, October 15th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $10.25.

Allarity Therapeutics Company Profile

Allarity Therapeutics, Inc. (NASDAQ: ALLR) is a clinical-stage biotechnology company focused on developing personalized treatments for cancer. The company uses its Drug Response Predictor (DRP) technology to analyze patient and tumor characteristics and identify individuals who may be more likely to respond to specific drug candidates. Allarity’s development programs have included stenoparib, also known as 2X-121, an orally administered PARP inhibitor being investigated for potential use in oncology.